<DOC>
	<DOCNO>NCT00143884</DOCNO>
	<brief_summary>This research project focus whether safe effective rely donor cell prevent relapse leukemia , lymphoma , blood cancer bone marrow stem cell transplant .</brief_summary>
	<brief_title>Study Low Intensity Conditioning Immunotherapy High-Risk Cancers Blood</brief_title>
	<detailed_description>This research project focus whether safe effective rely donor cell prevent relapse leukemia , lymphoma , blood cancer bone marrow stem cell transplant ( SCT ) . For many patient condition , bone marrow transplant chance cure . The standard type bone marrow transplant involve give high-doses chemotherapy radiation kill cancer cell follow infusion bone marrow stem cell relative bone marrow match . After transplant patient take anti-rejection drug many month prevent donor ’ immune cell cause severe reaction call Graft-versus-Host Disease ( GVHD ) , even fatal . However , patient certain type high-risk cancer even intense treatment effective cancer relapse . Is know many year bone marrow cell donor kill cancer cell . Recently , discover sometimes patient relapse bone marrow SCT cure give infusion donor white blood cell ( call donor leukocyte infusion DLI ) . By give DLI BEFORE relapse happen , hopefully relapse prevent . The high dos chemotherapy radiation therapy give prior standard bone marrow stem cell transplant make patient sick also increase chance get severe GVHD . In research study go rely mainly donor cell kill cancer cell , patient receive dosage chemotherapy low usual dosage . It think low intensity condition make transplant safer without risk relapse , however know whether low intensity conditioning safer standard conditioning .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Patient One follow hematological malignancy : 1 . Chronic myelogenous leukemia 1 . Accelerated phase 2 . Blast phase 2 . Acute myelogenous leukemia 1 . First great complete remission high risk feature : abnormality chromosome know poor prognosis 5 7 . 2 . Relapsed refractory patient ≤ 30 % blast 3 . Aged 55 year old disease state beyond first remission blast percentage &lt; 30 % . 3 . Acute lymphoblastic leukemia 1 . First complete remission high risk feature : ( 4 ; 11 ) 2 . Second complete remission relapse occur within first 12 month therapy 3 . Third great complete remission 4 . Relapsed refractory patient ≤ 30 % blast 5 . Aged 55 year old second disease state beyond first remission blast percentage &lt; 30 % . 4 . Myelodyplastic syndrome 1 . RAEB RAEBt patient , 55 year age old 2 . Any hematologic malignancy relapse follow autologous match related donor allogeneic stem cell transplant provide least 90 day elapse recent transplant 5 . NonHodgkin ’ Lymphoma 1 . 55 year old , fail anthracycline contain regimen tumor large 5 cm diameter . 2 . Patients rapidly progressive disease ineligible . 6 . Multiple myeloma patient , age , meet least one follow criterion : 1. disease refractory conventional chemotherapy VAD , pulse decadron , alkylating agent , OR 2. chromosomal abnormality cytogenetics FISH probe . 7 . Chronic lymphoblastic leukemia patient 1 . Any age 2 . Advanced disease ( Rai stage 3 4 ) 3 . Relapsed following/refractory alkylating agent nucleoside analog therapy 4 . NOTE : Patients bulky disease ( lymphadenopathy &gt; 5 cm ) progressive disease NOT eligible . 8 . Mantle cell lymphoma 1 . Any age 2 . Disease stage 3 4 3 . Lymphadenopathy must exceed 5 cm dimension 9 . Any eligible disease category , age , ineligible myeloablative conditioning organ dysfunction advance age ( 55 year old ) . Minimum organ function patient enter protocol define : 1 . Cardiac : Ejection fraction least 30 % . 2 . Renal : Creatinine &lt; 1.5 time normal age . 3 . Pulmonary : FEV1 FVC &gt; 60 % . 4 . Hepatic : Total bilirubin &lt; 2.0 AST/ALT &lt; 3 X institutional normal age . 5 . Performance ( adult ) : Karnofsky score must least 60 ; pt . 16 , Lansky score must least 60 . 10 . Low grade lymphoma ( small lymphocytic , follicular small cleave cell , follicular mix small cleave large cell ) must meet following criterion : 1. age 2. relapse refractory disease provide disease NOT rapidly progressive 3. lymphoma mass lymph node exceed 5 cm great dimension Age : age restriction Availability 6/6 HLA A , B , DR identical relative willing able donate allogeneic stem cell No active infection Serum creatinine less 1.5 time normal age Serum bilirubin le 1.5 time normal age Not pregnant . Patient HIV positive patient eligible Pregnant Donor 6/6 HLA match HLAA , B , DR Age 370 year , good general health No contraindication GCSF stimulation No contraindication leukapheresis peripheral blood stem cell Good general health Donor HIV positive history HIV risk factor Presence diseases transmissible blood pose unacceptable risk study subject . Pregnant Medical psychological condition would make donor unlikely tolerate GCSF injection leukapheresis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>